The earnings call highlighted significant restructuring savings and strong growth in the Plant Health business and new product pipeline. However, these positives are offset by challenges related to high inventory levels, pricing pressures, weaker than expected Q4 revenue, and substantial FX headwinds. Overall, the call reflects a cautious outlook with a focus on repositioning for future growth.
Company Guidance
During the Fourth Quarter 2024 Earnings Call, FMC Corporation outlined its guidance for 2025, focusing on several key metrics and strategic initiatives. The company anticipates full-year sales ranging from $4.15 billion to $4.35 billion, with an expected flat growth at the midpoint compared to 2024, despite the loss of approximately $110 million in sales from the Global Specialty Solutions divestiture. FMC projects an adjusted EBITDA between $870 million and $950 million, marking a 1% increase at the midpoint. The company also expects adjusted earnings per share to range from $3.26 to $3.70. FMC plans to reduce channel inventory significantly and is committed to decreasing inventory levels more than initially expected, which is anticipated to negatively impact 2025 financial performance. Additionally, FMC is implementing a newly developed strategy for its Rynaxypyr and Cyazypyr products and increasing investments in commercial development for new active ingredients. The company projects a 3% pricing decline, primarily due to contract adjustments with diamide partners based on reduced manufacturing costs. FX is expected to present a low to mid-single-digit headwind, impacting both sales and EBITDA. Despite these challenges, FMC is targeting significant growth in 2026 and 2027, with a focus on expanding its growth portfolio, including new active ingredients and plant health platforms.
Strong Restructuring Savings
Exceeded restructuring targets with $165 million in net savings delivered in 2024, and a clear line-of-sight to more than $250 million in run-rate savings by the end of 2025.
Plant Health Business Growth
The Plant Health business grew by 33% in Q4, driven mainly by the Biologicals segment, with expectations for continued mid-20% annual growth.
New Product Pipeline Progress
Fluindapyr and Isoflex active ingredients are expected to reach $150 million and $100 million in sales by 2025, respectively, with significant growth projected by 2027.
---
FMC (FMC) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FMC Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 04, 2025
$54.04
$35.92
-33.53%
Oct 29, 2024
$59.46
$65.82
+10.70%
Jul 31, 2024
$57.16
$63.01
+10.23%
May 06, 2024
$59.11
$64.71
+9.47%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Fmc Corp. (FMC) report earnings?
Fmc Corp. (FMC) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Fmc Corp. (FMC) earnings time?
Fmc Corp. (FMC) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.